Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study
Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study
ClinicalTrials.gov ID: NCT05947448
Sponsor: Hasten Biopharmaceutical Co., Ltd.
Information provided by: Hasten Biopharmaceutical Co., Ltd. (Responsible Party)
Last Update Posted: 2023-07-24
Brief Summary:
This is a national multicenter, prospective, observational study. It is planned to enroll 1215 patients with newly diagnosed essential hypertension in 80 centers, and divide them into 3 groups according to different treatment plans given by doctors: AZL-M monotherapy group, CCB monotherapy group (amlodipine besylate tablets or nifedipine controlled-release tablets) and AZL-M+CCB (amlodipine besylate tablets or nifedipine controlled-release tablets) combined treatment group. Subjects were visited 4 times at baseline, 1 month, 3 months, and 6 months, and the following key indicators of subjects were measured according to the doctor's decision, and the measurement results were collected
Official Title:
Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study
Intervention / Treatment:
- Drug: Azilsartan Medoxomil Potassium Tablet
- Drug: Nifedipine Sustained -release Tablets
- Drug: Levoamlodipine Maleate Table
| Category | Value |
|---|---|
| Study Start (Estimated) | 2023-09-25 |
| Primary Completion (Estimated) | 2025-12-25 |
| Study Completion (Estimated) | 2026-05-25 |
| Enrollment (Estimated) | 1215 |
| Study Type | Observational |
| Other Study ID Numbers |
Ph4-HST-EDA-C-NIS-22-01 |